Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,178 across all filing types
Latest filing 2024-01-23 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Loss of Share Certificates
Regulatory Filings Classification · 100% confidence The document is a compliance certificate under Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. It details the loss of share certificates and the stop transfer request related to those shares. The document is addressed to stock exchanges and signed by the company secretary. It is a regulatory compliance communication related to share certificate handling and does not contain financial data, management discussion, or report content. It is not an announcement of a report but a regulatory filing to comply with stock exchange regulations. Therefore, it fits best under Regulatory Filings (RNS). The document length is short (2929 characters), and it is a formal compliance certificate rather than a financial or management report.
2024-01-23 English
Lupin Receives Tentative Approval from U.S. FDA for Rivaroxaban Tablets USP.
Regulatory Filings Classification · 95% confidence The document is a press release dated January 23, 2024, announcing Lupin Limited's receipt of tentative approval from the U.S. FDA for its Abbreviated New Drug Application for Rivaroxaban Tablets. It is addressed to stock exchanges as a disclosure pursuant to Regulation 30 of SEBI Listing Regulations. The content is a corporate announcement about regulatory approval and product launch, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis. The document is a regulatory disclosure or announcement related to business operations and approvals. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-01-23 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release dated January 23, 2024, from Lupin Limited announcing the receipt of tentative approval from the U.S. FDA for their Abbreviated New Drug Application for Rivaroxaban Tablets. It is addressed to stock exchanges as a disclosure pursuant to Regulation 30 of SEBI Listing Regulations. The content is a corporate announcement about regulatory approval and product launch plans, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial data. The document is approximately 5,317 characters, which is relatively short and primarily serves as a regulatory disclosure and press release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and disclosures that do not fit other specific categories.
2024-01-23 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a compliance certificate under Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. It details the loss of share certificates and the stop transfer request related to those shares. The document is addressed to stock exchanges and signed by the company secretary. It is a regulatory compliance filing related to share certificate handling and does not contain financial statements, management discussion, or other report content. It is not an announcement of a report but a compliance certificate. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory compliance documents that do not fit other specific categories.
2024-01-19 English
Intimation regarding loss of share certificate by the shareholder.
Regulatory Filings Classification · 100% confidence The document is a compliance certificate under Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. It details the loss of share certificates and the request for stop transfer, addressed to stock exchanges. The document is short (2885 characters) and is a regulatory compliance communication rather than a financial report or announcement of financial results. It does not contain financial data, management discussion, or shareholder voting results. It is not an announcement of a report but a regulatory filing related to share certificate handling. Therefore, it fits best under Regulatory Filings (RNS).
2024-01-19 English
Lupin Receives Approval from U.S. FDA for Febuxostat Tablets.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the receipt of U.S. FDA approval for a pharmaceutical product by Lupin Limited. It is addressed to stock exchanges and references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) 2015, which pertains to disclosure requirements for listed companies. The content is a corporate announcement about a regulatory approval event, not a financial report, earnings release, or management discussion. The document length is 4317 characters, which is relatively short and consistent with a press release or regulatory announcement. There is no financial data, no detailed report, no voting results, no management changes, or other report types. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2024-01-18 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.